Skip to main content Skip to megamenu (after main content)
Meet us next:   AACR Annual Meeting 2025 – 27-30 April  ●  ISCT Conference 2025 – 7-9 May  ●  more on our events calendar

Corporate News

Page (8)

Alvetex Scaffold 384 well plates used in an Oncology HTS program by AstraZeneca

08 October 2014

Read more about how scientists at AstraZeneca in the UK are using Alvetex Scaffold in an automated Oncology HTS (High Throughput Screening) setting.

REPROCELL Acquires the iPS Cell Business Unit of Stemgent, Inc. (USA)

09 September 2014

REPROCELL announced that it will acquire the iPS Cell Business Unit of Stemgent, Inc. allowing REPROCELL to expand the product lineup of its iPSC Business

Stem Cell Company REPROCELL (Japan) Acquires 3D Cell Culture Company Reinnervate (UK) and Human Tissue Supplier BioServe (USA)

05 August 2014

Read about the Japanese regenerative medicine company REPROCELL Inc. and its acquisition of Reinnervate Ltd. (UK), and BioServe Inc. of MD, USA.

Scottish company creates first searchable database of human pharmacological responses in functional intact tissues

25 February 2014

Biopta Ltd, the human tissue-based contract research organisation, today announced a major development in discovery research with the launch of the first catalog of assays based on human functional tissues.

Launch of Reinnervate Perfusion System for 3D cell culture

05 February 2014

Read about Reinnervates announcement of the launch of a low-cost, simple system for combining 3D cell culture with dynamic circulation and perfusion of media.

Biopta collaborates with Merck to investigate in vivo cardiac effects

13 November 2013

In a recent collaboration with Merck, Biopta conducted human functional tissue experiments to investigate the mechanisms underlying two anti-arrhythmic drugs.

Reinnervate Ltd partners with Oncotest and SBH Sciences on introductory services for screening novel anti-cancer drugs using 3D tumour cell culture

04 November 2013

3D cell culture company Reinnervate Ltd today announced partnerships with two oncology-focussed CRO’s to offer 3D tumour cell screening services.

Reinnervate Ltd and Roslin Cellab to partner around 3D stem cell printing products and technologies

19 September 2013

Specialist 3D cell culture company Reinnervate Ltd today announced that it is entering into a collaboration with leading stem cell company Roslin Cellab to develop 3D stem cell printing products and services using Alvetex® technology.

Prof. Stefan Przyborski to participate at the XCellR8 Human Primary Cell Culture course, 7 November 2013

22 August 2013

Read the announcement that Reinnervate’s CSO, Professor Stefan Przyborski, will be participating at the XCellR8 Human Primary Cell Culture course.

Alvetex 3D cell culture scaffolds chosen by investigators at Massachusetts General Hospital for study of bone loss during space flight

31 July 2013

Alvetex Scaffold system has been chosen by a group at Massachusetts General Hospital for the first ever 3D osteocytic cell culture experiments in microgravity

Scottish SMEs Announce Collaboration with Universities, Industry and NHS in Establishment of a £20m Stratified Medicine Scotland Innovation Centre

23 April 2013

Today Scotland’s First Minister Alex Salmond announced the creation of a £20M Stratified Medicine Scotland Innovation Centre (SMS-IC), at the new South Glasgow Hospitals Campus.

3D cell culture firm Reinnervate and specialist Oncology CRO Oncotest GmbH enter collaboration agreement

07 January 2013

Learn more about how Oncotest is integrating Alvetex Scaffold 3d cell culture technology into its cancer research screening services.

3D cell culture firm Reinnervate announces the release of Alvetex®Scaffold 96 well plates for high throughput 3D cell-based assays

14 December 2012

Market leading 3D cell culture company, Reinnervate Ltd, today announced that it has launched and commenced shipments of Alvetex® Scaffold 96 well plates to customers.

Medicyte GmbH and Reinnervate Ltd to collaborate on development of next generation predictive 3D cell toxicity assays

09 July 2012

Read about a new product collaboration between two market leading companies in the field of cell based assays and predictive toxicology.

Top award for 3D cell culture pioneer, Stefan Przyborski, of Reinnervate Ltd

27 June 2012

Prof Stefan Przyborski, CSO and founder of Reinnervate Ltd has been recognised with a top award from the Royal Society of Chemistry.

Reinnervate and Tecan to develop automated 3D cell culture solutions for improved cellular assays

17 June 2012

Reinnervate Ltd and Tecan Trading AG, have signed a co-marketing agreement to develop a range of automated solutions for 3D cell culture, find out more.

Reinnervate Ltd and Roslin Cellab announce plans to collaborate

30 April 2012

Reinnervate Ltd and Roslin Cellab, two leading UK companies in the fields of 3D cell culture and stem cell biology, today announced that they will join forces to develop protocols for the three dimensional growth of human Embryonic Stem Cells (hESCs).

Reinnervate Ltd announce Kirkstall Ltd collaboration

30 March 2012

Reinnervate (inventors of Alvetex® Scaffold) and Kirkstall (developers of the Quasi-Vivo® system) today announced that they will collaborate to bring next generation three dimensional (3D) cell culture products to market in 2012.

Reinnervate and Mirus Bio announce collaboration with the launch of the new 3D Transfection System for the transfection of cells cultured in Alvetex®

16 November 2011

Read today's announcement that Reinnervate and Mirus Bio have entered into a commercial agreement to launch a new range of 3d cell culture products.

Alvetex® voted one of most technologically significant new research products by R&D magazine

27 June 2011

Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is delighted to announce that Alvetex®, its breakthrough 3D cell culture technology, is among the winners of the prestigious 49th Annual R&D 100 Awards.